CRISPR-Cas12 (clustered regularly interspaced short palindromic repeats-associated 12) detection method aiming at mycobacterium tuberculosis rpoB gene mutation and application
Through the optimized CRISPR-Cas12 detection method, combined with nested PCR and fluorescent probe technology, the time and cost problems of rifampicin resistance detection in the existing technology of Mycobacterium tuberculosis were solved, and the rapid and accurate rpoB gene was achieved. Mutation detection is suitable for use in primary hospitals.
Patent Information
- Application Number
- CN202411389356.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-08
- Publication Date
- 2024-11-05
AI Technical Summary
The prior art cannot quickly and accurately detect whether Mycobacterium tuberculosis has rifampicin resistance, especially due to its long-term bacterial culture and drug sensitivity testing process, and the high price of commercial kits and insufficient coverage sites, making it difficult to Promoted in grassroots hospitals.
Using the optimized CRISPR-Cas12 detection method, the design of specific sgRNAs to bind to rpoB gene mutation sites, and the nested PCR amplification and fluorescent probe technology can achieve efficient detection of rpoB gene mutations in Mycobacterium tuberculosis, overcoming CRISPR -The difficulty of the Cas12 system not recognizing single-base mutations.
It has achieved rapid and accurate detection of rpoB gene mutations in Mycobacterium tuberculosis, reduced detection costs, simplified operating procedures, promoted in grassroots hospitals, and improved the ability to identify drug resistance to rifampicin.
Smart Images

Figure CN118895375A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of molecular diagnosis and gene diagnosis, and specifically relates to a CRISPR-Cas12 detection method and application of rpoB gene mutation of Mycobacterium tuberculosis with natural PAM. Background Art
[0002] Tuberculosis caused by Mycobacterium tuberculosis infection is a global public health problem that cannot be ignored. According to WHO data, there were 10.6 million new tuberculosis patients in 2021, resulting in 1.6 million deaths. Among them, about 4.4% of Mycobacterium tuberculosis were insensitive to isoniazid and rifampicin, which ultimately led to 29% of tuberculosis deaths. Therefore, drug resistance of Mycobacterium tuberculosis poses a great challenge to the treatment of tuberculosis.
[0003] Bacterial culture strain identification and drug sensitivity testing are the gold standards for Mycobacterium tuberculosis and drug-resistant Mycobacterium tuberculosis. However, because tuberculosis is a slow-growing bacterium, the culture time is often as long as 8 weeks, and the drug sensitivity test takes even longer, which cannot accurately guide clinical drug use and has great limitations. Although the current commercial tuberculosis resistance detection kit GeneXpert® (USA) has improved specificity, the expensive reagents and consumables and special instrument prices make it difficult to promote in primary hospitals. In addition, it only detects two drug resistance sites, which is insufficient to cover the drug resistance sites of tuberculosis.
[0004] CRISPR-Cas12 is an emerging gene editing tool. In the CRISPR-Cas12 reaction system, the Cas12 nuclease is guided by sgRNA, binds to the matching DNA sequence and exerts nucleic acid fragment cutting activity. Since the CRISPR-Cas12 system has high sequence specificity and can identify the target sequence with high sensitivity, it is expected to be applied to the diagnosis of gene mutations.
[0005] The 81bp core region from codon 507 to codon 533 of the RNA polymerase β subunit (rpoB) gene of Mycobacterium tuberculosis largely determines whether Mycobacterium tuberculosis has rifampicin resistance. At the same time, the rpoB gene of Mycobacterium tuberculosis has a unique sequence that is different from non-tuberculous mycobacteria and other common respiratory pathogens, making it useful for the identification of Mycobacterium tuberculosis. Mutations in the rpoB gene lead to mutations in the RNA polymerase β subunit, which is the main mechanism leading to rifampicin resistance, and mutations at multiple sites can lead to the emergence of rifampicin resistance. Currently, more than 95% of clinically rifampicin-resistant Mycobacterium tuberculosis have mutations in the rpoB core region. The results of previous case sampling and sequencing showed that sites 526 and 516 are common sites where rpoB gene mutations lead to rifampicin resistance, and there are natural PAM sequences near sites 526 and 516. Therefore, detecting whether Mycobacterium tuberculosis has mutations at sites 526 and 516 is of great significance for identifying rifampicin resistance mutations. Summary of the invention
[0006] The purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and to provide a CRISPR-Cas12 detection method and application for tuberculosis resistance mutations with natural PAM. The CRISPR-Cas12 system is optimized and designed to overcome the difficulty that the general CRISPR-Cas12 system cannot recognize single-base mutations.
[0007] In one aspect, the present invention provides a detection kit for rpoB gene mutation of Mycobacterium tuberculosis, comprising: Nested PCR amplification system and CRISPR-Cas12 system; Wherein, the nested PCR amplification system includes an amplification primer set, and the primer set sequence includes: TB-1F: CCGACGACATCGACCACTT (SEQ ID NO: 1); TB-1R: GGTACGGCGTTTCGATGAAC (SEQ ID NO: 2); TB-2F: ACGTGGAGGCGATCACA (SEQ ID NO: 3); TB-2R: AGCCGATCAGACCGATGTT (SEQ ID NO: 4); The CRISPR-Cas12 system includes CRISPR-Cas12 nuclease, sgRNA-516 and / or sgRNA-526; wherein sgRNA-516 is selected from: UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUGG (SEQ ID NO: 5) UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUG (SEQ ID NO: 6); or UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCU (SEQ ID NO: 7); sgRNA-526 was selected from: UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGCG (SEQ ID NO: 8); UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGC (SEQ ID NO: 9); or UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGG (SEQ ID NO: 10).
[0008] In another embodiment, the nested PCR amplification system further includes a DNA polymerase and a buffer system. Nested PCR has been standardized, and the relevant DNA polymerase and buffer system can be obtained through various commercial channels. The PCR mix of the present invention is selected from Taq 2X PCR Mix V2 (RK20607) of abclonal, Taq PCRMix premix (B639293) of Shanghai Biotech, preferably Taq 2X PCR Mix V2 (RK20607) of abclonal. The DNA polymerase of the present invention is preferably Taq polymerase.
[0009] In another embodiment, the nested PCR amplification system further includes a TaqMan fluorescent probe. The two ends of the probe are respectively labeled with a reporter fluorescent group and a quencher fluorescent group. At the beginning, the probe is completely bound to any single strand of DNA, and the fluorescent signal emitted by the reporter group is absorbed by the quencher group, and no fluorescent signal is detected; during PCR amplification, the 5'-3' nuclease activity of the Taq enzyme will enzymatically degrade the probe, separate the reporter fluorescent group and the quencher fluorescent group, thereby emitting fluorescence, and the number of fluorescent molecules cut is proportional to the number of PCR products. Therefore, the purpose of detecting the amount of PCR product amplification can be achieved by detecting the fluorescence intensity in the PCR reaction system. The fluorescent probe TB-probe preferably used in the present invention is 6-FAM-CAGAACAACCCGCTGTCGG-BHQ1.
[0010] In another embodiment, the CRISPR-Cas12 nuclease of the present invention belongs to a type 2 V-type RNA-guided nuclease. The most studied in this protein family is the Cas12a nuclease, and the most commonly used Cas12a protein is from the BV3L6 strain of the genus Acidococcus and the bacteria of the family Lachnospiraceae (LbCas12a). The CRISPR-Cas12 nuclease preferably used in the present invention is selected from EnGen® Lba Cas12a (Cpf1) nuclease (M0653S) of NEB.
[0011] In another embodiment, the CRISPR-Cas12 system of the present invention further comprises a fluorescent probe. The probe is labeled with a reporter fluorescent group and a quencher fluorescent group at both ends. In another embodiment, the fluorescent probe of the present invention is selected from 6FAM-TTATT-BHQ1, HEX-TTATT-BHQ1 and 6FAM-TTGTT-BHQ1, preferably 6FAM-TTATT-BHQ1.
[0012] In another embodiment, the sgRNA-516 sequence described in the present invention is preferably UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUGG (SEQ ID NO: 5).
[0013] In another embodiment, the sgRNA-526 sequence described in the present invention is preferably UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGCG (SEQ ID NO: 8).
[0014] In another embodiment, the dosage range of sgRNA-516 described in the present invention is 5-150 ng, preferably 25-100 ng, such as 25 ng, 50 ng or 100 ng, preferably 25 ng.
[0015] In another embodiment, the dosage range of sgRNA-526 described in the present invention is 5-150 ng, preferably 25-100 ng, such as 25 ng, 50 ng or 100 ng, preferably 50 ng.
[0016] The second aspect of the present invention provides a CRISPR-Cas12 detection method and application for Mycobacterium tuberculosis rpoB gene mutation in the presence of natural PAM.
[0017] The present invention provides a CRISPR-Cas12 detection method for Mycobacterium tuberculosis rpoB gene mutation in the presence of a natural PAM, comprising the following steps: (1) Extract DNA from the sample to be tested; (2) The rpoB gene was amplified using two sets of primers using nested PCR, where the sequences of the nested PCR primer sets were: TB-1F: CCGACGACATCGACCACTT (SEQ ID NO: 1) TB-1R: GGTACGGCGTTTCGATGAAC (SEQ ID NO: 2) TB-2F: ACGTGGAGGCGATCACA (SEQ ID NO: 3) TB-2R:AGCCGATCAGACCGATGTT (SEQ ID NO: 4) (3) Incubate the nested PCR product, CRISPR-Cas12 nuclease, sgRNA and fluorescent probe in a suitable buffer system, and finally judge based on the fluorescence value: a. If the detection system emits fluorescence, the sample to be tested is a wild-type conjugated mycobacterium; or b. If the detection system does not emit fluorescence, the sample to be tested is rifampicin-resistant Mycobacterium tuberculosis with a mutation in the rpoB gene.
[0018] In another embodiment, in step (1) of the method of the present invention, the DNA of the sample to be tested can be extracted by itself using a standard method, or by using a commercial kit. The preferred extraction kit can be selected from the Bacterial Genomic DNA Rapid Extraction Kit (B518225) of Shanghai Bioengineering Corporation.
[0019] Sites 526 and 516 are common sites where rpoB gene mutations lead to rifampicin resistance, and natural PAM sequences exist near sites 526 and 516. In another embodiment, in step (1) of the method of the present invention, the DNA of the sample to be tested has natural PAM, wherein the natural PAM sequence near site 516 is TTC, and the natural PAM sequence near site 526 is TTG.
[0020] In another embodiment, in step (2) of the method of the present invention, a nested PCR primer set is used to efficiently amplify the rpoB gene of Mycobacterium tuberculosis in the sample to be tested. Compared with the negative control group without DNA addition, the fluorescence intensity of the conventional qPCR system is significantly higher when the sample concentration is less than 10 3 There was no significant difference after PCR, but the fluorescence intensity of the nested PCR system still had a significant difference when the sample concentration was 100 copies.
[0021] In another embodiment, in step (3) of the method, the CRISPR-Cas12 nuclease belongs to type 2 V-type RNA-guided endonucleases. The most studied protein family is Cas12a nuclease, and the most commonly used Cas12a protein is from the BV3L6 strain of the genus Acidococcus and the bacteria of the family Lachnospiraceae (LbCas12a). The CRISPR-Cas12 nuclease preferably used in the present invention is selected from EnGen® Lba Cas12a (Cpf1) nuclease (M0653S) of NEB.
[0022] In another embodiment, in step (3) of the method, sgRNA-516 is selected from: UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUGG (SEQ ID NO: 5); UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUG (SEQ ID NO: 6); or UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCU (SEQ ID NO: 7); sgRNA-526 was selected from: UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGCG (SEQ ID NO: 8); UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGC (SEQ ID NO: 9); or UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGG (SEQ ID NO: 10).
[0023] In another embodiment, in step (3) of the method, the sgRNA is preferably: sgRNA-516 (SEQ ID NO: 5): UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUGG; sgRNA-526 (SEQ ID NO: 8):UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGCG.
[0024] In another embodiment, in step (3) of the method, the amount of sgRNA-516 is in the range of 5-150 ng, preferably 25-100 ng, such as 25 ng, 50 ng or 100 ng, preferably 25 ng.
[0025] In another embodiment, in step (3) of the method, the amount of sgRNA-526 is in the range of 5-150 ng, preferably 25-100 ng, such as 25 ng, 50 ng or 100 ng, preferably 50 ng.
[0026] In another embodiment, in step (3) of the method, the fluorescent probe is selected from 6FAM-TTATT-BHQ1, HEX-TTATT-BHQ1, 6FAM-TTGTT-BHQ1, preferably 6FAM-TTATT-BHQ1.
[0027] In the method of the present invention, in step (3) of the method, the nested PCR product obtained in step (2), CRISPR-Cas12 nuclease, sgRNA and fluorescent probe are placed in a suitable buffer system for incubation. The sgRNA completely matches the wild-type Mycobacterium rpoB gene sequence, and there is at least 1nt mismatch with the resistant mutant sequence. Under appropriate incubation conditions, the CRISPR-Cas12 nuclease-sgRNA conjugate only reacts with the wild-type gene and activates the fluorescent probe to generate a fluorescent signal; in contrast, the CRISPR-Cas12 nuclease-sgRNA conjugate does not react with the mutant gene, and therefore cannot activate the fluorescent probe to generate a fluorescent signal, thereby achieving the purpose of gene identification. The fluorescent signal can be identified by a portable fluorescence instrument, and the corresponding fluorescent image can be captured by an intelligent mobile terminal, such as a smart phone.
[0028] The present invention provides a CRISPR-Cas12 detection method and application for tuberculosis resistance mutations with natural PAM, specifically including a nested PCR primer set and sgRNA for efficient amplification of Mycobacterium tuberculosis genes. The CRISPR-Cas12 system can be used to prepare a rifampicin resistance kit for detecting or assisting in the detection of multidrug-resistant Mycobacterium tuberculosis, which is convenient for Mycobacterium tuberculosis resistance genes, such as the detection of resistance mutation sites of rpoB resistance genes, and reduces the detection cost. In addition, compared with the CRISPR-Cas9 detection system, the CRISPR-Cas12 system has great advantages in reducing complex manual operations. In the CRISPR-Cas12 detection system, the PCR amplification product does not need to be purified and can be added to the CRISPR-Cas12 system system for enzyme digestion reaction. At the same time, since the CRISPR-Cas12 detection system can generate fluorescence during enzyme digestion, the enzyme digestion results can be read synchronously by a fluorescent quantitative PCR instrument, eliminating the complex agarose gel electrophoresis process. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 Comparison of amplification reactions between the nested PCR system and the common qPCR system. A is the dynamic fluorescence curve change and the Cq value of the amplification endpoint in the amplification reaction between the nested PCR system and the common qPCR system. B is the fluorescence intensity comparison of each sample concentration between the nested PCR system and the common qPCR system when the PCR reaction reaches the amplification endpoint.
[0030] Figure 2 This is the base sequence information near the antisense strand of codon 516 of the rpoB gene of Mycobacterium tuberculosis.
[0031] Figure 3 This is the base sequence information near the 526 codon of the rpoB gene of Mycobacterium tuberculosis on the forward chain.
[0032] Figure 4 Design ideas for sgRNA for detecting codons 516 and 526.
[0033] Figure 5 These are the fluorescence curves generated by the reaction of the Cas12-516sgRNA system with the wild-type sequence and the drug-resistant mutant sequence, respectively.
[0034] Figure 6 This is the result of placing the reaction liquid produced by the Cas12-516sgRNA system with the wild-type sequence and the drug-resistant mutant sequence in a portable fluorescence instrument.
[0035] Figure 7 These are the fluorescence curves generated by the reaction of the Cas12-526sgRNA system with the wild-type sequence and the drug-resistant mutant sequence, respectively.
[0036] Figure 8 This is the result of placing the reaction liquid produced by the Cas12-526sgRNA system with the wild-type sequence and the drug-resistant mutant sequence in a portable fluorescence instrument.
[0037] Fig. 9 This is the overall process of the CRISPR-Cas12 detection method. DETAILED DESCRIPTION
[0038] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention will be further described in detail below with reference to the accompanying drawings.
[0039] Example 1 Nested PCR amplification (1) Take the sample to be tested and extract DNA;
[0040] Follow the instructions of the bacterial genomic DNA rapid extraction kit (B518225) of Shanghai Bioengineering Company.
[0041] (2) Synthesize a nested PCR primer set for efficient amplification of the rpoB gene, the sequence of the primer set is: TB-1F: CCGACGACATCGACCACTT, TB-1R: GGTACGGCGTTTCGATGAAC, TB-2F: ACGTGGAGGCGATCACA, TB-2R: AGCCGATCAGACCGATGTT; TB-probe: CAGAACAACCCGCTGTCGG (3) Prepare the reaction solution according to the following formula: The pre-amplification PCR reaction components are shown in the following table:
[0042] (4) Then, a pre-amplification PCR reaction was performed. The pre-amplification PCR reaction conditions were as follows:
[0043] (5) After the pre-amplification reaction is completed, the final amplification reaction is carried out. The final amplification reaction conditions are as follows:
[0044] (6) Then, the final amplification PCR reaction was performed. The PCR reaction conditions were as follows:
[0045] The differences in the dynamic fluorescence curve changes and the Cq value results of the amplification endpoint in the nested PCR system and the common qPCR system are as follows: Figure 1 The results showed that the common qPCR system could 3 When the sample concentration is 100 copies, the Cq value is 15.5, and there is no positive Cq result in the negative control group. Figure 1 B is the fluorescence intensity comparison of the nested PCR system and the common qPCR system at each sample concentration when the PCR reaction reaches the end point of amplification. The results show that compared with the negative control group without DNA addition, the fluorescence intensity of the common qPCR system is lower when the sample concentration is less than 10 3 There was no significant difference after PCR, but the fluorescence intensity of the nested PCR system still had a significant difference when the sample concentration was 100 copies.
[0046] Example 2 CRISPR-Cas12 system for gene identification The base sequence information near the antisense strand of codon 516 of the rpoB gene of Mycobacterium tuberculosis is as follows Figure 2 As shown, the 516 codon of the rpoB gene in drug-sensitive Mycobacterium tuberculosis is GAC, while the 516 codon of the rpoB gene in drug-resistant Mycobacterium tuberculosis may mutate to GTC, TAC, AAC, etc. The yellow box in the chromatogram is the position of the 516 codon, and the PAM sequence required by the CRISPR-Cas12 system exists at the blue box mark (TTC) position of the first two bases. According to this PAM sequence position, the Cas12-sgRNA system for distinguishing GAC from GTC, TAC, and AAC was subsequently designed.
[0047] Figure 3 It is the base sequence information near the 526 codon of the rpoB gene of Mycobacterium tuberculosis on the forward chain. The 526 codon of the rpoB gene in drug-susceptible Mycobacterium tuberculosis is CAC, while the 526 codon of the rpoB gene in drug-resistant Mycobacterium tuberculosis may mutate to GAC, CTC, TAC, etc. The yellow box in the chromatogram is the position of the 526 codon. The PAM sequence required by the CRISPR-Cas12 system exists at the blue box mark (TTG) of the first three bases. According to the position of this PAM sequence, the Cas12-sgRNA system for distinguishing CAC from GAC, CTC, and TAC was subsequently designed.
[0048] Figure 4 The sgRNA design idea for detecting codons 516 and 526 is that the sgRNA completely matches the wild-type sequence and has at least 1nt mismatch with the drug-resistant mutant sequence. Therefore, the subsequent Cas12-sgRNA only reacts with the wild-type gene but not the mutant gene, achieving the purpose of gene identification.
[0049] sgRNA-516 (SEQ ID NO: 5): UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUGG; sgRNA-526 (SEQ ID NO: 8): UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGCG.
[0050] Place the nested PCR product, CRISPR-Cas12 nuclease, sgRNA and fluorescent probe in a suitable buffer system and incubate them. Finally, judge based on the fluorescence value: a. If the detection system emits fluorescence, the sample to be tested is a wild-type conjugated mycobacterium; or b. If the detection system does not emit fluorescence, the sample to be tested is rifampicin-resistant Mycobacterium tuberculosis with a mutation in the rpoB gene.
[0051] The reaction system is as follows:
[0052] Figure 5 The fluorescence curves produced by the reaction of the Cas12-516sgRNA system designed using the above method with the wild-type sequence and the drug-resistant mutant sequence, respectively, are shown in the figure. The purple line (upward curve) is the wild-type sequence PCR product sample, and the green line (bottom curve) is the GTC, TAC, AAC genotype drug-resistant tuberculosis PCR product sample and the negative control without adding DNA samples. It can be seen that in the 30-minute incubation reaction, the fluorescence intensity of the wild-type sequence PCR product sample represented by the purple line showed an increasing trend over time, while the fluorescence intensity of the GTC, TAC, AAC genotype drug-resistant tuberculosis PCR product sample represented by the green line did not change much, and there was no significant difference from the negative control without adding DNA samples.
[0053] Figure 6 The Cas12-516sgRNA system designed using the above method, respectively reacted with the wild-type sequence and the drug-resistant mutant sequence to produce the reaction solution placed in a portable fluorescence instrument. The first reaction chamber is the wild-type sequence sample, the second to seventh reaction chambers are the GTC, TAC, AAC genotype samples, and the eighth reaction chamber is the negative control without adding DNA samples. It can be seen that after 30 minutes of reaction, the wild-type sequence PCR product sample emits visible green fluorescence in the portable fluorescence instrument, while the GTC, TAC, AAC genotype drug-resistant tuberculosis PCR product samples and the negative control without adding DNA samples have no obvious difference.
[0054] Figure 7 The fluorescence curves produced by the reaction of the Cas12-526sgRNA system designed using the above method with the wild-type sequence and the drug-resistant mutant sequence, respectively, are shown in the figure. The purple line (upward curve) is the wild-type sequence PCR product sample, and the green line (bottom curve) is the GAC, CTC, TAC genotype drug-resistant tuberculosis PCR product sample and the negative control without adding DNA sample. It can be seen that in the 30-minute incubation reaction, the fluorescence intensity of the wild-type sequence PCR product sample represented by the purple line showed an increasing trend over time, while the fluorescence intensity of the GAC, CTC, TAC genotype drug-resistant tuberculosis PCR product sample represented by the green line did not change much, and there was no significant difference from the negative control without adding DNA sample.
[0055] Figure 8The Cas12-526sgRNA system designed using the above method, respectively reacted with the wild-type sequence and the drug-resistant mutant sequence to produce the reaction solution placed in a portable fluorescence instrument. The first reaction chamber is the wild-type sequence sample, the second to fourth reaction chambers are GAC, CTC, TAC genotype samples, and the fifth reaction chamber is a negative control without adding DNA samples. It can be seen that after 30 minutes of reaction, the wild-type sequence PCR product sample emits visible green fluorescence in the portable fluorescence instrument, while the drug-resistant tuberculosis PCR product samples of GAC, CTC, TAC genotypes and the negative control without adding DNA samples have no obvious difference.
[0056] Fig. 9 The overall process of the CRISPR-Cas12 detection method is shown. After obtaining the body fluid specimen, DNA extraction and double-round nested PCR amplification are performed first, and the fluorescence curve read by the fluorescence quantitative PCR instrument is observed to determine whether Mycobacterium tuberculosis is present in the specimen. After confirming the presence of Mycobacterium tuberculosis, the amplified product is added to the CRISPR-Cas12 detection system, and the fluorescence curve read by the fluorescence quantitative PCR instrument is observed to confirm whether there are gene mutations at sites 516 and 526 of the rpoB gene to obtain drug resistance results.
[0057] The above disclosure is only a preferred embodiment of the present invention, which cannot be used to limit the scope of the present invention. Therefore, equivalent changes made according to the claims of the present invention are still within the scope of the present invention.
Claims
1. A detection kit for rpoB gene mutation of Mycobacterium tuberculosis, include: Nested PCR amplification system and CRISPR-Cas12 system; Wherein, the nested PCR amplification system includes an amplification primer set, and the primer set sequence includes: TB-1F: CCGACGACATCGACCACTT (SEQ ID NO: 1); TB-1R: GGTACGGCGTTTCGATGAAC (SEQ ID NO: 2); TB-2F: ACGTGGAGGCGATCACA (SEQ ID NO: 3); TB-2R: AGCCGATCAGACCGATGTT (SEQ ID NO: 4); The CRISPR-Cas12 system includes CRISPR-Cas12 nuclease, sgRNA-516 and / or sgRNA-526; wherein sgRNA-516 is selected from: UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUGG (SEQ ID NO: 5); UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUG (SEQ ID NO: 6); or UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCU (SEQ ID NO: 7); sgRNA-526 was selected from: UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGCG (SEQ ID NO: 8); UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGC (SEQ ID NO: 9); or UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGG (SEQ ID NO: 10).
2. The detection kit according to claim 1, Features: The nested PCR amplification system further comprises DNA polymerase and a buffer system.
3. The detection kit according to claim 1, Features: The nested PCR amplification system further includes a TaqMan fluorescent probe.
4. The detection kit according to claim 1, Features: The CRISPR-Cas12 nuclease belongs to Class 2 V-type RNA-guided endonucleases, derived from the BV3L6 strain of the genus Acidaminococcus or from the bacteria of the family Lachnospiraceae (LbCas12a).
5. The detection kit according to claim 1, Features: The CRISPR-Cas12 system further includes a fluorescent probe, which is selected from 6FAM-TTATT-BHQ1, HEX-TTATT-BHQ1 or 6FAM-TTGTT-BHQ1.
6. A detection kit for Mycobacterium tuberculosis rpoB gene mutation, include: Nested PCR amplification system and CRISPR-Cas12 system; The nested PCR amplification system includes a nested PCR primer set, a DNA polymerase, a buffer system and a TaqMan fluorescent probe; Wherein, the nested PCR amplification system includes an amplification primer set, and the primer set sequence includes: TB-1F: CCGACGACATCGACCACTT (SEQ ID NO: 1); TB-1R: GGTACGGCGTTTCGATGAAC (SEQ ID NO: 2); TB-2F: ACGTGGAGGCGATCACA (SEQ ID NO: 3); TB-2R: AGCCGATCAGACCGATGTT (SEQ ID NO: 4); Among them, the DNA polymerase was Taq polymerase, and the fluorescent probe was 6-FAM-CAGAACAACCCGCTGTCGG-BHQ1; Wherein, the CRISPR-Cas12 system includes CRISPR-Cas12 nuclease, fluorescent probe, sgRNA-516 and / or sgRNA-526; The sequence of sgRNA-516 is: UAAUUUCUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUGG (SEQ ID NO: 5); The sequence of sgRNA-526 is: UAAUUUCUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGCG (SEQ ID NO: 8); Wherein, the fluorescent probe is 6FAM-TTATT-BHQ1; Wherein, the CRISPR-Cas12 nuclease is selected from the BV3L6 strain of the genus Acidaminococcus or the bacteria of the family Lachnospiraceae (LbCas12a).
7. A CRISPR-Cas12 detection method for Mycobacterium tuberculosis rpoB gene mutations in the presence of natural PAM, comprising the following steps: (1) Extract DNA from the sample to be tested; (2) The rpoB gene was amplified using two sets of primers using nested PCR, where the sequences of the nested PCR primer sets were: TB-1F: CCGACGACATCGACCACTT (SEQ ID NO: 1); TB-1R: GGTACGGCGTTTCGATGAAC (SEQ ID NO: 2); TB-2F: ACGTGGAGGCGATCACA (SEQ ID NO: 3); TB-2R: AGCCGATCAGACCGATGTT (SEQ ID NO: 4); (3) Incubate the nested PCR product, CRISPR-Cas12 nuclease, sgRNA and fluorescent probe in a suitable buffer system, and finally judge based on the fluorescence value: a. If the detection system emits fluorescence, the sample to be tested is a wild-type conjugated mycobacterium; or b. If the detection system does not emit fluorescence, the sample to be tested is rifampicin-resistant Mycobacterium tuberculosis with a mutation in the rpoB gene.
8. The CRISPR-Cas12 detection method according to claim 7, Features: In step (3) of the method, sgRNA-516 is selected from: UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUGG (SEQ ID NO: 5); UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUG (SEQ ID NO: 6); or UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCU (SEQ ID NO: 7); sgRNA-526 was selected from: UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGCG (SEQ ID NO: 8); UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGC (SEQ ID NO: 9); or UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGG (SEQ ID NO: 10).
9. The CRISPR-Cas12 detection method according to claim 7, Features: In step (3) of the method, the fluorescent probe is selected from 6FAM-TTATT-BHQ1, HEX-TTATT-BHQ1 or 6FAM-TTGTT-BHQ1.
10. The CRISPR-Cas12 detection method according to claim 7, Features: In step (1) of the method, the DNA of the sample to be tested can be extracted by itself using a standard method, or by using a commercial kit; the DNA of the sample to be tested has a natural PAM, wherein the natural PAM sequence near the 516 site is TTC, and the natural PAM sequence near the 526 site is TTG; In step (3) of the method, the CRISPR-Cas12 nuclease is selected from the BV3L6 strain of the genus Acidiococcus or the bacteria of the family Lachnospiraceae (LbCas12a); the amount of sgRNA-526 and sgRNA-516 in the sgRNA is in the range of 5-150 ng, wherein sgRNA-526 is: UAAUUUCUACUAAGUGUAGAUACCCACAAGCGCCGACUGUCGGCG; sgRNA-516 is: UAAUUUCUACUAAGUGUAGAUUGGUCCAUGAAUUGGCUCAGCUGG; The fluorescent probe is 6FAM-TTATT-BHQ1.
Citation Information
Patent Citations
Nucleic acid rapid detection kit for streptomycin drug-resistant mycobacterium tuberculosis and detection method thereof
CN112725487A
CrRNA for detecting rifampicin drug resistance point mutation of mycobacterium tuberculosis based on CRISPR-Cas technology
CN114107300A
CRISPR / Cas12a detection kit based on asymmetric RPA and application of CRISPR / Cas12a detection kit
CN117004775A
Cited By
CRISPR (clustered regularly interspaced short palindromic repeats) system and kit for detecting drug-resistant tuberculosis
CN119876441A
A CRISPR system and kit for detecting drug-resistant tuberculosis
CN119876441B
Method for detecting mycobacterium paratuberculosis based on CRISPR-Cas12a technology
CN120843659A
A method for detecting mycobacterium paratuberculosis based on CRISPR-cas12a technology
CN120843659B
